|
|||||||
|
Fusion Protein:MEIS2-GALK2 |
Fusion Gene and Fusion Protein Summary |
 Fusion gene summary |
| Fusion partner gene information | Fusion gene name: MEIS2-GALK2 | FusionPDB ID: 52897 | FusionGDB2.0 ID: 52897 | Hgene | Tgene | Gene symbol | MEIS2 | GALK2 | Gene ID | 4212 | 2585 |
| Gene name | Meis homeobox 2 | galactokinase 2 | |
| Synonyms | CPCMR|HsT18361|MRG1 | GK2 | |
| Cytomap | 15q14 | 15q21.1-q21.2 | |
| Type of gene | protein-coding | protein-coding | |
| Description | homeobox protein Meis2Meis homolog 2Meis1, myeloid ecotropic viral integration site 1 homolog 2Meis1-related gene 1TALE homeobox protein Meis2meis1-related protein 1 | N-acetylgalactosamine kinasegalNAc kinase | |
| Modification date | 20200313 | 20200313 | |
| UniProtAcc | O14770 Main function of 5'-partner protein: FUNCTION: Involved in transcriptional regulation. Binds to HOX or PBX proteins to form dimers, or to a DNA-bound dimer of PBX and HOX proteins and thought to have a role in stabilization of the homeoprotein-DNA complex. Isoform 3 is required for the activity of a PDX1:PBX1b:MEIS2b complex in pancreatic acinar cells involved in the transcriptional activation of the ELA1 enhancer; the complex binds to the enhancer B element and cooperates with the transcription factor 1 complex (PTF1) bound to the enhancer A element; MEIS2 is not involved in complex DNA-binding. Probably in complex with PBX1, is involved in transcriptional regulation by KLF4. Isoform 3 and isoform 4 can bind to a EPHA8 promoter sequence containing the DNA motif 5'-CGGTCA-3'; in cooperation with a PBX protein (such as PBX2) is proposed to be involved in the transcriptional activation of EPHA8 in the developing midbrain. May be involved in regulation of myeloid differentiation. Can bind to the DNA sequence 5'-TGACAG-3'in the activator ACT sequence of the D(1A) dopamine receptor (DRD1) promoter and activate DRD1 transcription; isoform 5 cannot activate DRD1 transcription. {ECO:0000269|PubMed:10764806, ECO:0000269|PubMed:11279116, ECO:0000269|PubMed:21746878}. | Q01415 Main function of 5'-partner protein: FUNCTION: Acts on GalNAc. Also acts as a galactokinase when galactose is present at high concentrations. May be involved in a salvage pathway for the reutilization of free GalNAc derived from the degradation of complex carbohydrates. {ECO:0000269|PubMed:16006554}. | |
| Ensembl transtripts involved in fusion gene | ENST ids | ENST00000219869, ENST00000338564, ENST00000340545, ENST00000382766, ENST00000397620, ENST00000397624, ENST00000424352, ENST00000444725, ENST00000557796, ENST00000559085, ENST00000559561, ENST00000561208, ENST00000559408, | ENST00000543495, ENST00000544523, ENST00000559454, ENST00000561014, ENST00000327171, ENST00000396509, ENST00000560031, |
| Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0) | * DoF score | 25 X 16 X 6=2400 | 9 X 8 X 5=360 |
| # samples | 27 | 10 | |
| ** MAII score | log2(27/2400*10)=-3.15200309344505 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(10/360*10)=-1.84799690655495 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Fusion gene context | PubMed: MEIS2 [Title/Abstract] AND GALK2 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Fusion neoantigen context | PubMed: MEIS2 [Title/Abstract] AND GALK2 [Title/Abstract] AND neoantigen [Title/Abstract] | ||
| Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | MEIS2(37375972)-GALK2(49611801), # samples:1 | ||
| Anticipated loss of major functional domain due to fusion event. | MEIS2-GALK2 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. MEIS2-GALK2 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. MEIS2-GALK2 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. MEIS2-GALK2 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. MEIS2-GALK2 seems lost the major protein functional domain in Hgene partner, which is a essential gene due to the frame-shifted ORF. MEIS2-GALK2 seems lost the major protein functional domain in Hgene partner, which is a transcription factor due to the frame-shifted ORF. MEIS2-GALK2 seems lost the major protein functional domain in Tgene partner, which is a cell metabolism gene due to the frame-shifted ORF. | ||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | MEIS2 | GO:0045931 | positive regulation of mitotic cell cycle | 26512644 |
| Hgene | MEIS2 | GO:0045944 | positive regulation of transcription by RNA polymerase II | 10764806 |
| Hgene | MEIS2 | GO:0110024 | positive regulation of cardiac muscle myoblast proliferation | 26512644 |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr15:37375972/chr15:49611801) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here. |
| Fusion gene breakpoints across MEIS2 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
 |
| Fusion gene breakpoints across GALK2 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
 |
Top |
Fusion Amino Acid Sequences |
| Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| ENST00000561208 | MEIS2 | chr15 | 37375972 | - | ENST00000327171 | GALK2 | chr15 | 49611801 | + | 3229 | 1173 | 404 | 1582 | 392 |
| ENST00000561208 | MEIS2 | chr15 | 37375972 | - | ENST00000560031 | GALK2 | chr15 | 49611801 | + | 1942 | 1173 | 404 | 1582 | 392 |
| ENST00000561208 | MEIS2 | chr15 | 37375972 | - | ENST00000396509 | GALK2 | chr15 | 49611801 | + | 1938 | 1173 | 404 | 1582 | 392 |
| ENST00000382766 | MEIS2 | chr15 | 37375972 | - | ENST00000327171 | GALK2 | chr15 | 49611801 | + | 3847 | 1791 | 1022 | 2200 | 392 |
| ENST00000382766 | MEIS2 | chr15 | 37375972 | - | ENST00000560031 | GALK2 | chr15 | 49611801 | + | 2560 | 1791 | 1022 | 2200 | 392 |
| ENST00000382766 | MEIS2 | chr15 | 37375972 | - | ENST00000396509 | GALK2 | chr15 | 49611801 | + | 2556 | 1791 | 1022 | 2200 | 392 |
| ENST00000557796 | MEIS2 | chr15 | 37375972 | - | ENST00000327171 | GALK2 | chr15 | 49611801 | + | 3204 | 1148 | 397 | 1557 | 386 |
| ENST00000557796 | MEIS2 | chr15 | 37375972 | - | ENST00000560031 | GALK2 | chr15 | 49611801 | + | 1917 | 1148 | 397 | 1557 | 386 |
| ENST00000557796 | MEIS2 | chr15 | 37375972 | - | ENST00000396509 | GALK2 | chr15 | 49611801 | + | 1913 | 1148 | 397 | 1557 | 386 |
| ENST00000397620 | MEIS2 | chr15 | 37375972 | - | ENST00000327171 | GALK2 | chr15 | 49611801 | + | 3271 | 1215 | 725 | 1624 | 299 |
| ENST00000397620 | MEIS2 | chr15 | 37375972 | - | ENST00000560031 | GALK2 | chr15 | 49611801 | + | 1984 | 1215 | 725 | 1624 | 299 |
| ENST00000397620 | MEIS2 | chr15 | 37375972 | - | ENST00000396509 | GALK2 | chr15 | 49611801 | + | 1980 | 1215 | 725 | 1624 | 299 |
| ENST00000559561 | MEIS2 | chr15 | 37375972 | - | ENST00000327171 | GALK2 | chr15 | 49611801 | + | 3065 | 1009 | 240 | 1418 | 392 |
| ENST00000559561 | MEIS2 | chr15 | 37375972 | - | ENST00000560031 | GALK2 | chr15 | 49611801 | + | 1778 | 1009 | 240 | 1418 | 392 |
| ENST00000559561 | MEIS2 | chr15 | 37375972 | - | ENST00000396509 | GALK2 | chr15 | 49611801 | + | 1774 | 1009 | 240 | 1418 | 392 |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
| ENST00000561208 | ENST00000327171 | MEIS2 | chr15 | 37375972 | - | GALK2 | chr15 | 49611801 | + | 0.001934007 | 0.998066 |
| ENST00000561208 | ENST00000560031 | MEIS2 | chr15 | 37375972 | - | GALK2 | chr15 | 49611801 | + | 0.005261122 | 0.9947389 |
| ENST00000561208 | ENST00000396509 | MEIS2 | chr15 | 37375972 | - | GALK2 | chr15 | 49611801 | + | 0.00533578 | 0.9946642 |
| ENST00000382766 | ENST00000327171 | MEIS2 | chr15 | 37375972 | - | GALK2 | chr15 | 49611801 | + | 0.002133078 | 0.9978669 |
| ENST00000382766 | ENST00000560031 | MEIS2 | chr15 | 37375972 | - | GALK2 | chr15 | 49611801 | + | 0.006479509 | 0.99352044 |
| ENST00000382766 | ENST00000396509 | MEIS2 | chr15 | 37375972 | - | GALK2 | chr15 | 49611801 | + | 0.006559848 | 0.9934402 |
| ENST00000557796 | ENST00000327171 | MEIS2 | chr15 | 37375972 | - | GALK2 | chr15 | 49611801 | + | 0.001230899 | 0.9987691 |
| ENST00000557796 | ENST00000560031 | MEIS2 | chr15 | 37375972 | - | GALK2 | chr15 | 49611801 | + | 0.007195171 | 0.9928048 |
| ENST00000557796 | ENST00000396509 | MEIS2 | chr15 | 37375972 | - | GALK2 | chr15 | 49611801 | + | 0.007327178 | 0.99267274 |
| ENST00000397620 | ENST00000327171 | MEIS2 | chr15 | 37375972 | - | GALK2 | chr15 | 49611801 | + | 0.000442424 | 0.99955755 |
| ENST00000397620 | ENST00000560031 | MEIS2 | chr15 | 37375972 | - | GALK2 | chr15 | 49611801 | + | 0.003531935 | 0.99646807 |
| ENST00000397620 | ENST00000396509 | MEIS2 | chr15 | 37375972 | - | GALK2 | chr15 | 49611801 | + | 0.003607194 | 0.9963928 |
| ENST00000559561 | ENST00000327171 | MEIS2 | chr15 | 37375972 | - | GALK2 | chr15 | 49611801 | + | 0.001933319 | 0.9980667 |
| ENST00000559561 | ENST00000560031 | MEIS2 | chr15 | 37375972 | - | GALK2 | chr15 | 49611801 | + | 0.006787187 | 0.9932128 |
| ENST00000559561 | ENST00000396509 | MEIS2 | chr15 | 37375972 | - | GALK2 | chr15 | 49611801 | + | 0.006890043 | 0.99310994 |
| Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones. |
Get the fusion protein sequences from here. |
| Fusion protein sequence information is available in the fasta format. >FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP |
Top |
Fusion Protein Breakpoint Sequences for MEIS2-GALK2 |
| +/-13 AA sequence from the breakpoints of the fusion protein sequences. |
| Hgene | Hchr | Hbp | Tgene | Tchr | Tbp | Length(fusion protein) | BP in fusion protein | Peptide |
| MEIS2 | chr15 | 37375972 | GALK2 | chr15 | 49611801 | 1009 | 256 | GHASQSGDNSSEQVLIFKLYQRAKHV |
| MEIS2 | chr15 | 37375972 | GALK2 | chr15 | 49611801 | 1148 | 250 | GHASQSGDNSSEQVLIFKLYQRAKHV |
| MEIS2 | chr15 | 37375972 | GALK2 | chr15 | 49611801 | 1173 | 256 | GHASQSGDNSSEQVLIFKLYQRAKHV |
| MEIS2 | chr15 | 37375972 | GALK2 | chr15 | 49611801 | 1215 | 163 | GHASQSGDNSSEQVLIFKLYQRAKHV |
| MEIS2 | chr15 | 37375972 | GALK2 | chr15 | 49611801 | 1791 | 256 | GHASQSGDNSSEQVLIFKLYQRAKHV |
Top |
Potential FusionNeoAntigen Information of MEIS2-GALK2 in HLA I |
| Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific. |
| MEIS2-GALK2_37375972_49611801.msa |
| Potential FusionNeoAntigen Information * We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5) |
| Fusion gene | Hchr | Hbp | Tgene | Tchr | Tbp | HLA I | FusionNeoAntigen peptide | Binding score | Immunogenic score | Neoantigen start (at BP 13) | Neoantigen end (at BP 13) |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-B44:03 | SEQVLIFKL | 0.999 | 0.768 | 10 | 19 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-B13:01 | SEQVLIFKL | 0.9976 | 0.6338 | 10 | 19 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-B15:17 | NSSEQVLIF | 0.9908 | 0.6828 | 8 | 17 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-B45:01 | SEQVLIFKL | 0.9798 | 0.579 | 10 | 19 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-B18:01 | SEQVLIFKL | 0.9743 | 0.616 | 10 | 19 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-B35:01 | NSSEQVLIF | 0.9689 | 0.7319 | 8 | 17 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-B44:03 | EQVLIFKLY | 0.9613 | 0.7508 | 11 | 20 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-B15:02 | EQVLIFKLY | 0.9587 | 0.6935 | 11 | 20 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-B57:03 | NSSEQVLIF | 0.8637 | 0.7762 | 8 | 17 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-B41:01 | SEQVLIFKL | 0.5327 | 0.6803 | 10 | 19 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-B39:13 | SEQVLIFKL | 0.4415 | 0.6575 | 10 | 19 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-B44:03 | SEQVLIFKLY | 0.9998 | 0.7427 | 10 | 20 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-B18:01 | SEQVLIFKLY | 0.9844 | 0.5506 | 10 | 20 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-C05:09 | SGDNSSEQV | 0.9998 | 0.9564 | 5 | 14 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-C08:15 | SGDNSSEQV | 0.9993 | 0.9793 | 5 | 14 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-B15:21 | NSSEQVLIF | 0.9892 | 0.758 | 8 | 17 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-C15:04 | NSSEQVLIF | 0.9878 | 0.8366 | 8 | 17 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-B15:21 | EQVLIFKLY | 0.9525 | 0.5893 | 11 | 20 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-C03:14 | NSSEQVLIF | 0.9045 | 0.9583 | 8 | 17 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-C12:12 | NSSEQVLIF | 0.7344 | 0.8045 | 8 | 17 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-B39:08 | SEQVLIFKL | 0.5861 | 0.6105 | 10 | 19 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-C12:04 | NSSEQVLIF | 0.542 | 0.9847 | 8 | 17 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-C06:03 | NSSEQVLIF | 0.5375 | 0.9827 | 8 | 17 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-B39:08 | GDNSSEQVL | 0.4034 | 0.8917 | 6 | 15 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-C08:15 | SGDNSSEQVL | 0.9998 | 0.9746 | 5 | 15 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-C04:03 | SGDNSSEQV | 0.9998 | 0.9334 | 5 | 14 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-C05:01 | SGDNSSEQV | 0.9998 | 0.9564 | 5 | 14 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-C08:02 | SGDNSSEQV | 0.9993 | 0.9793 | 5 | 14 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-B44:13 | SEQVLIFKL | 0.999 | 0.768 | 10 | 19 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-B44:07 | SEQVLIFKL | 0.999 | 0.768 | 10 | 19 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-B44:26 | SEQVLIFKL | 0.999 | 0.768 | 10 | 19 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-C03:02 | NSSEQVLIF | 0.9984 | 0.907 | 8 | 17 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-C15:09 | NSSEQVLIF | 0.9878 | 0.8366 | 8 | 17 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-B15:27 | EQVLIFKLY | 0.9862 | 0.5117 | 11 | 20 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-B35:11 | NSSEQVLIF | 0.9831 | 0.7579 | 8 | 17 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-B15:50 | EQVLIFKLY | 0.9806 | 0.5861 | 11 | 20 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-B57:02 | NSSEQVLIF | 0.9787 | 0.6087 | 8 | 17 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-B18:08 | SEQVLIFKL | 0.9786 | 0.5045 | 10 | 19 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-B18:05 | SEQVLIFKL | 0.9743 | 0.616 | 10 | 19 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-B18:06 | SEQVLIFKL | 0.9725 | 0.6138 | 10 | 19 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-B18:04 | EQVLIFKLY | 0.9704 | 0.5039 | 11 | 20 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-B35:23 | NSSEQVLIF | 0.97 | 0.7253 | 8 | 17 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-B35:77 | NSSEQVLIF | 0.9689 | 0.7319 | 8 | 17 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-B44:26 | EQVLIFKLY | 0.9613 | 0.7508 | 11 | 20 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-B44:13 | EQVLIFKLY | 0.9613 | 0.7508 | 11 | 20 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-B44:07 | EQVLIFKLY | 0.9613 | 0.7508 | 11 | 20 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-B15:20 | EQVLIFKLY | 0.9507 | 0.5453 | 11 | 20 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-B35:20 | EQVLIFKLY | 0.9408 | 0.5828 | 11 | 20 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-B15:24 | EQVLIFKLY | 0.9375 | 0.5338 | 11 | 20 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-B35:28 | EQVLIFKLY | 0.9279 | 0.5568 | 11 | 20 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-B18:03 | SEQVLIFKL | 0.9237 | 0.6071 | 10 | 19 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-B18:11 | SEQVLIFKL | 0.9029 | 0.5181 | 10 | 19 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-B35:43 | NSSEQVLIF | 0.8866 | 0.6076 | 8 | 17 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-C16:04 | NSSEQVLIF | 0.8748 | 0.9491 | 8 | 17 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-B35:24 | NSSEQVLIF | 0.8521 | 0.7467 | 8 | 17 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-C12:02 | NSSEQVLIF | 0.8354 | 0.9267 | 8 | 17 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-C12:03 | NSSEQVLIF | 0.7667 | 0.9491 | 8 | 17 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-C16:01 | NSSEQVLIF | 0.7107 | 0.9472 | 8 | 17 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-B48:02 | EQVLIFKLY | 0.5596 | 0.5242 | 11 | 20 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-C16:02 | NSSEQVLIF | 0.5243 | 0.977 | 8 | 17 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-B39:31 | SEQVLIFKL | 0.4746 | 0.6605 | 10 | 19 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-B39:02 | SEQVLIFKL | 0.4558 | 0.6662 | 10 | 19 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-C02:10 | NSSEQVLIF | 0.2632 | 0.9321 | 8 | 17 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-C02:02 | NSSEQVLIF | 0.2632 | 0.9321 | 8 | 17 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-B44:07 | SEQVLIFKLY | 0.9998 | 0.7427 | 10 | 20 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-B44:26 | SEQVLIFKLY | 0.9998 | 0.7427 | 10 | 20 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-B44:13 | SEQVLIFKLY | 0.9998 | 0.7427 | 10 | 20 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-C08:02 | SGDNSSEQVL | 0.9998 | 0.9746 | 5 | 15 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-B18:06 | SEQVLIFKLY | 0.9844 | 0.5444 | 10 | 20 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-B18:05 | SEQVLIFKLY | 0.9844 | 0.5506 | 10 | 20 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | HLA-B18:03 | SEQVLIFKLY | 0.9755 | 0.5392 | 10 | 20 |
Top |
Potential FusionNeoAntigen Information of MEIS2-GALK2 in HLA II |
| Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific. |
| MEIS2-GALK2_37375972_49611801.msa |
| Potential FusionNeoAntigen Information * We used NetMHCIIpan v4.1 (%rank<0.5). |
| Fusion gene | Hchr | Hbp | Tgene | Tchr | Tbp | HLA II | FusionNeoAntigen peptide | Neoantigen start (at BP 13) | Neoantigen end (at BP 13) |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | DRB1-1204 | SEQVLIFKLYQRAKH | 10 | 25 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | DRB1-1209 | SEQVLIFKLYQRAKH | 10 | 25 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | DRB5-0106 | SEQVLIFKLYQRAKH | 10 | 25 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | DRB5-0202 | SEQVLIFKLYQRAKH | 10 | 25 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | DRB5-0202 | SSEQVLIFKLYQRAK | 9 | 24 |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 | DRB5-0204 | SEQVLIFKLYQRAKH | 10 | 25 |
Top |
Fusion breakpoint peptide structures of MEIS2-GALK2 |
| 3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens * The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA. |
| File name | BPseq | Hgene | Tgene | Hchr | Hbp | Tchr | Tbp | AAlen |
| 2714 | GDNSSEQVLIFKLY | MEIS2 | GALK2 | chr15 | 37375972 | chr15 | 49611801 | 1791 |
Top |
Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of MEIS2-GALK2 |
| Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens * We used Glide to predict the interaction between HLAs and neoantigens. |
| HLA allele | PDB ID | File name | BPseq | Docking score | Glide score |
| HLA-B14:02 | 3BVN | 2714 | GDNSSEQVLIFKLY | -7.15543 | -7.26883 |
| HLA-B14:02 | 3BVN | 2714 | GDNSSEQVLIFKLY | -4.77435 | -5.80965 |
| HLA-B52:01 | 3W39 | 2714 | GDNSSEQVLIFKLY | -6.80875 | -6.92215 |
| HLA-B52:01 | 3W39 | 2714 | GDNSSEQVLIFKLY | -4.20386 | -5.23916 |
| HLA-A11:01 | 4UQ2 | 2714 | GDNSSEQVLIFKLY | -7.5194 | -8.5547 |
| HLA-A11:01 | 4UQ2 | 2714 | GDNSSEQVLIFKLY | -6.9601 | -7.0735 |
| HLA-A24:02 | 5HGA | 2714 | GDNSSEQVLIFKLY | -7.52403 | -7.63743 |
| HLA-A24:02 | 5HGA | 2714 | GDNSSEQVLIFKLY | -5.82433 | -6.85963 |
| HLA-B27:05 | 6PYJ | 2714 | GDNSSEQVLIFKLY | -3.28285 | -4.31815 |
| HLA-B44:05 | 3DX8 | 2714 | GDNSSEQVLIFKLY | -5.91172 | -6.94702 |
| HLA-B44:05 | 3DX8 | 2714 | GDNSSEQVLIFKLY | -4.24346 | -4.35686 |
Top |
Vaccine Design for the FusionNeoAntigens of MEIS2-GALK2 |
| mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is. |
| Fusion gene | Hchr | Hbp | Tchr | Tbp | Start in +/-13AA | End in +/-13AA | FusionNeoAntigen peptide sequence | FusionNeoAntigen RNA sequence |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 10 | 19 | SEQVLIFKL | GTGAGCAAGTGCTCATCTTCAAACTCT |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 10 | 20 | SEQVLIFKLY | GTGAGCAAGTGCTCATCTTCAAACTCTATC |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 11 | 20 | EQVLIFKLY | AGCAAGTGCTCATCTTCAAACTCTATC |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 5 | 14 | SGDNSSEQV | GCGGAGACAACAGCAGTGAGCAAGTGC |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 5 | 15 | SGDNSSEQVL | GCGGAGACAACAGCAGTGAGCAAGTGCTCA |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 6 | 15 | GDNSSEQVL | GAGACAACAGCAGTGAGCAAGTGCTCA |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 8 | 17 | NSSEQVLIF | ACAGCAGTGAGCAAGTGCTCATCTTCA |
| mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs. |
| Fusion gene | Hchr | Hbp | Tchr | Tbp | Start in +/-13AA | End in +/-13AA | FusionNeoAntigen peptide | FusionNEoAntigen RNA sequence |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 10 | 25 | SEQVLIFKLYQRAKH | GTGAGCAAGTGCTCATCTTCAAACTCTATCAGCGGGCAAAGCATG |
| MEIS2-GALK2 | chr15 | 37375972 | chr15 | 49611801 | 9 | 24 | SSEQVLIFKLYQRAK | GCAGTGAGCAAGTGCTCATCTTCAAACTCTATCAGCGGGCAAAGC |
Top |
Information of the samples that have these potential fusion neoantigens of MEIS2-GALK2 |
| These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens. |
| Cancer type | Fusion gene | Hchr | Hbp | Henst | Tchr | Tbp | Tenst | Sample |
| KIRC | MEIS2-GALK2 | chr15 | 37375972 | ENST00000382766 | chr15 | 49611801 | ENST00000327171 | TCGA-BP-4165-01A |
Top |
Potential target of CAR-T therapy development for MEIS2-GALK2 |
| Predicted 3D structure. We used RoseTTAFold. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features * Minus value of BPloci means that the break point is located before the CDS. |
| - In-frame and retained 'Transmembrane'. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Subcellular localization prediction of the transmembrane domain retained fusion proteins * We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image. |
| Hgene | Hchr | Hbp | Henst | Tgene | Tchr | Tbp | Tenst | DeepLoc result |
Top |
Related Drugs to MEIS2-GALK2 |
| Drugs used for this fusion-positive patient. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Drug | Source | PMID |
Top |
Related Diseases to MEIS2-GALK2 |
| Diseases that have this fusion gene. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Disease | Source | PMID |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Copyright 2023-PresentThe University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information
Campus Carry|Site Policies